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Abstract Hypnic headache (HH) is a primary headache
disorder, which occurs exclusively during sleep and usually
begins after 50 years of age. There are no controlled trials
for the treatment of HH. We reviewed all the available
papers, including 119 cases published in literature up to
date, reporting the efficacy of the medications used to treat
HH. Acute treatment is not recommended, since no drug
proved to be clearly effective and also because the intensity
and the duration of the attacks do not require the intake of a
medication in most cases. As for prevention, a wide variety
of medications were reported to be of benefit in HH. The
drugs that were found to be effective in at least five cases
are: lithium, indomethacin, caffeine and flunarizine. Lith-
ium was the most extensively studied compound and
demonstrated to be an efficacious treatment in 32 cases.
Unfortunately, despite its efficacy, significant adverse
effects and poor tolerability are not rare, mainly in elderly
patients. Many patients reported a good response to indo-
methacin, but some could not tolerate it. Caffeine and
melatonin treatments did not yield robust evidence to rec-
ommend their use as single preventive agents. Nevertheless,
their association with lithium or indomethacin seems to
produce an additional therapeutic efficacy. A course of
lithium should be tried first, followed 3–4 months later by
tapering. If headache recurs during tapering, a longer
duration of therapy may be needed. If lithium treatment
does not provide a significant response, indomethacin can
be commenced as second-line approach. If these treatments
prove to be ineffective or poorly tolerated, other agents,
such as caffeine and melatonin, can be administered.
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Background
Hypnic headache (HH) is a primary headache disorder,
which occurs exclusively during sleep and usually begins
after 50 years of age. Raskin first described the disorder in
1988 [1]; more than 100 cases have been subsequently
reported. In the largest case series, HH was diagnosed in
0.07–0.1% of all headache patients assessed annually at a
specialty clinic, reflecting the relative rarity of this condi-
tion [2]. HH usually begins late in life with a mean age at
onset of 62 ± 11 years, with a range of 36-84 years. The
mean duration of disease before diagnosis is 5 ± 7 years
(range 0.1–35 years), suggesting that this condition is
poorly recognized and perhaps underdiagnosed [2]. Three
cases of probable HH in childhood and adolescence have
been reported [3–5], although the occurrence at this age
does not meet International Headache Society (IHS)
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criteria. The condition is more prevalent in women (65%)
than in men; in a personal large case series, we found a
greater majority of females, accounting for 87.9% [6]. No
case with a family history of HH has been reported so far.
Table 1 lists the International Classification of Headache
Disorders Classification, 2nd edition (ICHD-II) criteria for
HH, that was included into group 4 (code 4.5), in the
subheading of ‘‘Other primary headaches’’ [7].
Intracranial disorders must be excluded. Distinction
from one of the trigeminal cephalalgias, in particular
cluster headache, is necessary for effective management.
The pain of HH is usually mild to moderate, but severe
pain is reported by approximately 20% of patients. HHs
occur in most cases at a consistent time each night, usually
between 1:00 and 3:00 a.m., and may on rare instances
occur during a daytime nap [2]. Pain is mainly bilateral,
being unilateral in one-third of cases. It is usually localized
anteriorly; on occasion it involves the occiput or radiates
into the neck. The attacks usually last from 15 to 180 min,
even if longer durations have been described. The fre-
quency of attacks is usually high. More than 4 attacks per
week occur in 70% of the cases and about half of patients
have daily attacks [2]. Associated autonomic symptoms
accompany the pain in approximately 8% of sufferers, and
nausea, photophobia and phonophobia may rarely be
present. The natural history of HH is not well known. It is
assumed that it tends to be chronic unremitting, but only a
few patients have been observed for at least 2 years. Some
authors have classified HH into two different forms,
chronic and episodic form. The episodic form is further
subdivided into two types, episodic with no recurrence, and
relapsing and remitting variety. Episodic form without
recurrence may show spontaneous resolution or sustained
remission even after withdrawal of the effective drug [5, 8,
9]. In view of previously published data, we proposed that
HH be divided in two subtypes, chronic and episodic. We
suggested that episodes of this disorder with remission
periods of C1 month should be denoted by the term
‘‘episodic HH’’ and for those patients who have not
experienced a remission over a period of at least 1 year, the
disorder should be called ‘‘chronic HH’’ [8]. Some symp-
tomatic cases have also been described, in which HH was
linked to the onset of an intracranial lesion or disappeared
after its removal. These cases were found to be secondary
to a posterior fossa meningioma [10], a growth hormone-
secreting pituitary tumour [11], and a nonfunctioning
pituitary macroadenoma [12], respectively. Other cases of
symptomatic HH related to obstructive sleep apnoea syn-
drome [13], ischaemic stroke in the midrostral upper pons
[14], nocturnal arterial hypertension [15] and medication
(ergotamine) overuse [16]. The exact pathophysiological
mechanisms of HH have not yet been elucidated. It has
been postulated that HH may be the result of a chronobi-
ological disorder, serotonin, and melatonin dysregulation
or a disturbance of rapid eye movement (REM) sleep. In
most of the patients with HH who had polysomnographic
studies, attacks were associated with REM sleep [2, 13, 17–
22]; however, non-REM related HHs have also been
reported [23–26]. In a recent paper reporting the results of
polysomnography in 7 subjects whose HH attacks were
recorded during the sleep studies, 3 patients had their
headache attacks exclusively during non-REM sleep, 2
patients in REM sleep and the other 2 patients having both
[9]. Furthermore, HH might be a chronobiological distur-
bance [27], because many patients experience the headache
attack always at the same time in the night (‘‘alarm-clock
headache’’). The most important brain structure for the
endogenous circadian rhythm is the suprachiasmatic nuclei
(SCN). The SCN have afferent and efferent projections
with the periaqueductal grey and aminergic nuclei, which
are the most important brainstem structures for pain mod-
ulation. With advanced age, the function of the hypotha-
lamic-pineal axis, and in particular of the SCN, is
diminished, and melatonin secretion is impaired or absent
after the age of 60 years [2, 28–30]. The variety of drugs
reported to be effective in HH (see below) also underscores
the possibility that the pathophysiology might be hetero-
geneous. It is probable, given the differences in medication
response and in polysomnographic studies, that more than
one pathophysiological mechanism is responsible for HH.
Further investigations using sleep studies and functional
neuroimaging are necessary to better understand this
syndrome.
Treatment
In the following paragraphs, we summarize the information
collected from a systematic analysis of the international
literature on the treatment of HH. We conducted a baseline
literature search covering the period 1980–2009,
Table 1 ICHD-II criteria for hypnic headache
Description: attacks of dull headache that always awaken the
patient from sleep
Diagnostic criteria
A. Dull headache fulfilling criteria B–D
B. Develops only during sleep, and awakens patient
C. At least two of the following characteristics
1. Occurs [15 times per month
2. Lasts C15 min after waking
3. First occurs after age of 50 years
D. No autonomic symptoms and no more than one of nausea,
photophobia or phonophobia
E. Not attributed to another disorder
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employing available electronic databases (National Library
of Medicine, National Institute of Health, Embase) with the
following medical search terms: hypnic headache, alarm-
clock headache, nocturnal headache. Whenever available,
chapters of book were also consulted and considered.
No controlled trials for the treatment of HH were found.
Acute medications in the attack were tested only in a few
patients. Notably, subcutaneous sumatriptan and oxygen
inhalation, the treatments of first choice for cluster head-
ache attacks, were not effective. Acetylsalicylic acid, caf-
feine and acetaminophen demonstrated, on average, only a
mild efficacy for the acute relief of HH attacks. From the
standpoint of preventive medications reported, lithium was
used most frequently and also showed the best average
efficacy. Lithium was the first treatment reported to be
effective for HH [1]; this drug interacts with the pain-
modulating system possibly involved in this disorder and
seems to increase indirectly nocturnal production of mel-
atonin. Moreover, lithium may exert an enhancing effect on
cerebral serotonin functions. Lithium carbonate can be
initiated at 300 mg at night and increased to 600 mg after 1
or 2 weeks if necessary [1, 9]. A good response was also
noted with lower doses, even 150 mg at bedtime [8]. Out of
the patients treated with lithium, this drug was discontinued
in 5 cases [1, 31–33] despite its efficacy, due to significant
adverse effects. Poor tolerability to lithium is not rare,
mainly in elderly patients. Renal and thyroid function
should be assessed before initiating therapy, and periodi-
cally during treatment. Serum lithium concentrations
should be monitored as well to avoid toxicity. Side effects
include tremor, diarrhoea, increased thirst and polyuria.
Recently, a transient HH was described in a patient with
bipolar disorder after the withdrawal of long-term lithium
treatment [34]. Many other agents that have been reported
to effectively treat HH include bedtime doses of caffeine
(40–60 mg tablet, or as a cup of coffee), indomethacin,
flunarizine, tricyclic antidepressants, verapamil, predni-
sone, topiramate, gabapentin, melatonin, benzodiazepines,
pregabalin and acetazolamide. Curiously, of the patients
treated with caffeine before bedtime, a disrupted sleep
pattern was reported only in a few cases [27, 35]. The
efficacy of indomethacin is of special interest because this
drug is also effective in paroxysmal hemicrania and hem-
icrania continua [36]. It has been suggested that indo-
methacin may be helpful in those patients whose HH
attacks are unilateral [31]. It was shown to be effective in
extremely variable doses, ranging from 25 mg to 150 mg/
day. Some patients who responded to indomethacin before
bedtime developed daytime headaches, which resolved
after indomethacin was discontinued. This phenomenon
was termed as ‘‘the paradox of indomethacin’’, whose most
prominent side effect and reason for discontinuation
(headache) is the very symptom for which it provides a
remarkable therapeutic efficacy [31]. Other patients
reported a good response to indomethacin, but could not
tolerate it [21, 37]. Interestingly, the efficacy of topiramate,
at the dose of 25 mg at bedtime and 100 mg/day was
recently reported in two cases [33, 38]. A list of all drugs,
both acute and prophylactic, that provided some benefit and
their efficacy, as reported by the respective authors, is
presented in Tables 2 and 3, respectively. In a personal
large case series, including 33 patients, that was recently
published as an abstract [6], we found that the most
effective treatments were caffeine (7 cases), indomethacin
(4 cases), melatonin (4 cases), lithium at low
doses ? caffeine (3 cases), lithium (1 case) and verapamil
(1 case). The remaining 13 cases reported no benefit,
refused the treatment or did not need any medication, since
they were pain-free after an episodic period. Based on the
literature review and our study results, we suggest a
Table 2 Different acute drug
treatments in the published case
reports on hypnic headache
Drugs References No. cases Efficacy
Good Moderate None
Acetylsalicylic acid [18, 39] 2 1 1
Acetylsalicylic acid ? caffeine [27] 1 1
Caffeine [35, 41] 3 1 2
Acetaminophen [4, 19, 33, 40] 4 1 1 2
Sumatriptan 50 mg ? caffeine [27] 1 1
Nimesulide [19, 32, 33, 42] 4 1 3
Ibuprofen [5, 32] 2 1 1
Triptans others than sumatriptan [5, 32, 33, 39] 4 1 3
Ergotamine [40] 1 1
Sumatriptan 50–100 mg [5, 19, 31, 33] 4 4
Oxygen inhalation [5, 13, 18] 3 3
Indomethacin [19, 33] 2 2
Sumatriptan 6 mg s.c. [18] 1 1
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practical approach to the management of HH, which is
shown in Fig. 1. Although some patients may specifically
ask for an acute treatment, this is not recommended, since
no drug showed to be clearly effective; furthermore, the
mild-to-moderate intensity and the short duration of the
attacks do not require the intake of acute medications in
most cases. The attacks subside spontaneously in a rela-
tively short time, almost never exceeding the duration of 2–
3 h. Moreover, the intensity is mild to moderate in the
majority of cases. The patients themselves are more con-
cerned with the prevention of the headaches, rather than
with the treatment of the single attacks. As for prophylaxis,
a course of 300–600 mg lithium should be tried first, on
some instances in association with caffeine and/or mela-
tonin, followed, 3–4 months later, by tapering. If headache
recurs during tapering, a longer duration of therapy may be
needed. The treatment with caffeine and in particular with
melatonin alone did not yield robust evidence to
Table 3 Different prophylactic drug treatments in the published case reports on hypnic headache
Drugs References No. cases Efficacy
Good Moderate None
Lithium [1, 8, 9, 13, 17, 19, 20, 23, 32, 33, 36, 38, 40, 41, 43–48] 47 32 10 5
Lithium ? caffeine [8, 35] 4 4
Lithium ? dothiepin ? alprazolam [40] 1 1
Lithium ? venlafaxine [49] 1 1
Lithium ? amitriptyline [41] 1 1
Indomethacin [5, 21–23, 27, 31, 32, 35, 37, 44, 46, 49–52] 22 10 3 9
Indomethacin ? caffeine [31, 41] 2 1 1
Caffeine [8, 18, 27, 31, 32, 39, 41, 50–52] 15 5 4 6
Caffeine ? melatonin [32] 2 2
Flunarizine [9, 17–19, 32, 33, 38, 41, 53, 54] 13 5 1 7
Flunarizine ? melatonin [54] 1 1
Tricyclic antidepressants [5, 18, 19, 23, 25, 26, 31, 33, 39, 41] 14 2 2 10
Prednisone [8, 13, 27, 32, 38, 42] 7 2 1 4
Verapamil [18, 19, 31, 32] 5 2 3
Verapamil ? amitryptiline [18] 1 1
Topiramate [33, 38] 2 2
Gabapentin [23, 32, 52] 3 1 1 1
Melatonin [31, 52] 4 1 3
Benzodiazepines [13, 19] 2 1 1
Atenolol 25 mg [27] 1 1
Pregabalin [52] 1 1
Acetazolamide [37] 1 1
Botulinum toxin type A [39] 1 1
Cinnarizine [32] 1 1
Ergotamine ? phenobarbital [27] 1 1
Acetylsalicylic acid ? caffeine [27] 1 1
Eszopiclone [55] 1 1
Clorazepate ? venlafaxine ? valproate [34] 1 1
Oxetorone [48] 8 8
Atenolol 50 mg [32, 41] 3 2 1
Propranolol [5, 13, 19, 33] 7 7
Antidepressants others than tricyclics [5, 13, 23, 39, 49] 6 6
Pizotifen [19, 23, 32, 33, 38] 4 4
Methysergide [13, 23] 3 3
Valproate [5, 19, 33] 3 3
Ergotamine [31] 1 1
Acetylsalicylic acid [31] 1 1
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recommend their use as single preventive agents. Their
association with the recommended medications (i.e. lith-
ium and indomethacin) seems to produce an additional
overall therapeutic efficacy. Anyway, some patients
responded completely to caffeine given alone at bedtime. If
lithium treatment does not provide a significant response,
as second line approach indomethacin can be commenced,
at a dose ranging from 25 to 75 mg at bedtime; based on
the above remarks, caffeine can also be tried, alone or in
combination with indomethacin. If these treatments prove
to be ineffective, other medications, such as verapamil,
flunarizine or topiramate, can be administered. These drugs
are also recommended when lithium and indomethacin are
contraindicated or are related to significant side effects.
Conflict of interest None.
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